Norifaz (Risedronate Sodium)

Risedronate sodium, the active ingredient in Norifaz, is a bisphosphonate presented as an oral tablet for oral use. It is used to treat osteoporosis and Paget's disease of bone in adult patients, helping to strengthen bone and reduce fracture risk.

GNH USA supplies Norifaz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for healthcare providers across multiple regions and ensures timely delivery to meet urgent needs.

Norifaz, a bisphosphonate, acts on bone remodeling pathways to treat conditions characterized by excessive bone turnover.

- Osteoporosis: improves bone mineral density and reduces risk of vertebral and non‑vertebral fractures. - Paget's disease of bone: normalizes abnormal bone remodeling and alleviates bone pain. - Male osteoporosis: increases bone strength and lowers fracture incidence in men with low bone mass.

Risedronate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Abdominal pain - Dyspepsia - Nausea - Musculoskeletal pain

Serious or Rare Side Effects: - Osteonecrosis of the jaw - Atypical femur fracture - Severe allergic reaction (anaphylaxis)

Before initiating Norifaz, several safety considerations should be reviewed to minimize risk.

- Assess renal function: avoid use in severe renal impairment (creatinine clearance <30 mL/min). - Ensure adequate calcium and vitamin D intake: maintain recommended daily amounts to support bone health. - Take on an empty stomach: swallow tablet with plain water at least 30 minutes before food or other medications. - Monitor for esophageal symptoms: discontinue and seek medical advice if pain or difficulty swallowing occurs. - Review concomitant medications: check for potential interactions with NSAIDs, antacids, or other bisphosphonates. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Risedronate can interact with other medicines, affecting its absorption or increasing adverse effect risk.

Major Interactions (Avoid): - Concomitant use with other bisphosphonates: may increase bone toxicity. - Calcium, iron, or multivitamin supplements taken within 2 hours: markedly reduce risedronate absorption. - NSAIDs or corticosteroids: heighten risk of gastrointestinal irritation or ulceration.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may modestly decrease drug bioavailability. - Antacids containing aluminum or magnesium: can lower absorption; separate dosing by at least 30 minutes. - Diuretics (loop or thiazide): monitor serum calcium levels for potential hypocalcemia.